West Coast Biotech Roundup: Otonomy, Oncothyreon, Gilead, & More

(Page 2 of 3)

human health and well being. The institute is providing space for as many as 15 startups. HTL Life plans to provide as much as $250,000 in seed funding to each company admitted to the accelerator.

—Gilead’s  (NASDAQ: GILD) chief scientist told the Financial Times that the Foster City, CA-based biotech is on the hunt for acquisitions while it goes prospecting for a drug as successful as its hepatitis C drug. Norbert Bischofberger, Gilead’s executive vice president of research and development, said the pharma is looking particularly for target companies that have drugs that are already proven to work in early-stage trials.

—Pfizer and BioAtla, based in San Diego and Beijing, have agreed to work together to develop and market new antibody therapies based on Pfizer’s antibody-drug conjugate payloads and BioAtla’s conditionally active biologics technology. Under their licensing agreement, Pfizer gets an exclusive option to commercialize BioAtla CAB antibodies targeting CTLA4, a validated immuno-oncology target in humans. BioAtla could earn as much as $1 billion under terms of the deal.

—Novato, CA-based Raptor Pharmaceuticals (NASDAQ: RPTP) said Thursday it plans to push ahead in a pivotal study of its drug for Huntington’s Disease, even though results from a Phase 2/3 trial had no statistical significance. Raptor said the results were clinically meaningful because … Next Page »

Single Page Currently on Page: 1 2 3 previous page